Capitol Vein Blog

Monday, May 21, 2012

Varisolve, a New Treatment for Varicose Veins

Recent news reports have drawn attention to an effective new varicose vein therapy known as Varisolve®. This technique involves injecting a foamed sclerotherapy agent directly into the saphenous vein to encourage ablation and absence of flow. Drs. Garth Rosenberg and Paul McNeill both participated in the Varisolve trial and contributed to the data that is now being presented to the FDA for approval (a decision is expected later this year).

One unique aspect of the foam used in the Varisolve procedure is the admixture of CO2 instead of room air, which may allow for safer outcomes. Additionally, Varisolve can be performed without the need for local anesthesia and may be better tolerated in certain patients. 

The current medical standard for treating varicose veins is VNUS Closure (now known as the Venefit Procedure), which uses heat to cause vein ablation.  Currently, Venefit is the optimal method to treat saphenous vein reflux, the usual cause of painful varicose veins. It is not yet clear how Varisolve results will compare to Venefit for similar patients. The data for Venefit is excellent, with long lasting results and highly effective outcomes for most patients with saphenous vein reflux. However, as the data for Varisolve becomes available, we may find indications for its use as well.  

If you have questions about any of the current or pending treatments for varicose veins, please see us as any of the Maryland, Virginia or West Virginia offices.


Post a Comment